SEC Filings
Alkermes Gives Teva A Royalty-Free Path To LYBALVI Generics Starting In 2039
Pediatric exclusivity would move licensed entry to 2040, while the settlement permits an earlier launch under certain circumstances.
Alkermes (ALKS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Pediatric exclusivity would move licensed entry to 2040, while the settlement permits an earlier launch under certain circumstances.
Earnings
The drugmaker's latest quarterly report says Avadel's stand-alone net income can no longer be presented, while LUMRYZ sales reached $226.0 million.
Earnings
LUMRYZ added $89.9 million in sales, yet Avadel deal costs and new interest expense cut net income from $82.8 million.
Earnings
Blair Jackson, in his first call as CEO, said Alkermes would adjust its pricing once Takeda sets its own within weeks.